Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bioextrax AB (BIOEX) Fair Value & Analysis

Industrials · SE · Market cap 121M SEK

Pricekr 2.47
Fair Valuekr 2.01
Upside-18.6%
Quality95/100
Evidence: Low Range kr 1.50 – kr 2.51

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Bioextrax AB (BIOEX) currently trades at kr 2.47, while our model-based Fair Value estimate is kr 2.01 — implying the stock looks roughly 18.6% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. The company harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids, as well as microfibers from feathers. Bioextrax AB (publ) was incorporated in 2014 and is based in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Waste Management, Inc (WM) -42% UWS (UWS) -37% Republic Services, Inc (RSG) -42% Waste Connections, Inc (WCN) -44% Veolia Environnement SA (VEOEF) -13% Clean Harbors, Inc (CLH) -46%

Frequently asked questions

Is Bioextrax AB (BIOEX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 2.01 versus a price of kr 2.47 — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BIOEX?
Our 21-model fair value for Bioextrax AB is kr 2.01 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 2.47.
What is the quality score of BIOEX?
Bioextrax AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.